Corcept Therapeutics reported that adding relacorilant to chemotherapy reduced risk of death by 35% in a Phase 3 ovarian cancer study, a result the company said will shape its regulatory path forward. The survival benefit updates earlier interim data and comes after Corcept faced an FDA rejection for a Cushing's indication; the new oncology data give the biotech positive momentum. The Phase 3 results (published and summarized in company releases and coverage) show improved overall survival and reinforce relacorilant’s potential in platinum-resistant and hard-to-treat ovarian cancer settings. Investors and analysts will watch the company’s next regulatory submissions and whether the survival signal supports accelerated or regular approval pathways.